Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

close

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel

Return to Activity: Relapsed/Refractory Mantle Cell Lymphoma and BTK Inhibitors: Expert Exchange and Discussion

CME/CE Test

Relapsed/Refractory Mantle Cell Lymphoma and BTK Inhibitors: Expert Exchange and Discussion

The development of treatment resistance to covalent BTK inhibitors is potentiated by which of the following?

Demethylation of multidrug resistance gene

A Cys481 mutation in the adenosine triphosphate (ATP) binding pocket of BTK

BTK gene amplification

Inhibition of apoptosis
In the BGB-3111-206 trial, investigating the efficacy and safety of zanubrutinib in relapsed/refractory mantle cell lymphoma, what was the achieved objective response?

48%

63%

84%

98%
In the phase I/II study investigating the efficacy and safety of orelabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma, what was the achieved objective response rate?

31%

48%

63%

83%

Find Us On

About

About Medscape Privacy Policy Editorial Policy Cookies Do Not Sell My Personal Information Terms of Use Advertising Policy Help Center

Membership

Become a Member About You Professional Information Newsletters & Alerts Market Research

App

Medscape

WebMD Network

Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK

Editions

English Deutsch Español Français Português UK